The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial.
Shinya Ueda
No relevant relationships to disclose
Shuichi Hironaka
No relevant relationships to disclose
Hirofumi Yasui
No relevant relationships to disclose
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Yakult Honsha
Masahiro Tsuda
No relevant relationships to disclose
Takehiko Tsumura
No relevant relationships to disclose
Naotoshi Sugimoto
No relevant relationships to disclose
Hideki Shimodaira
No relevant relationships to disclose
Shinya Tokunaga
No relevant relationships to disclose
Toshikazu Moriwaki
No relevant relationships to disclose
Taito Esaki
No relevant relationships to disclose
Michitaka Nagase
No relevant relationships to disclose
Kazumasa Fujitani
No relevant relationships to disclose
Kensei Yamaguchi
No relevant relationships to disclose
Takashi Ura
No relevant relationships to disclose
Yasuo Hamamoto
No relevant relationships to disclose
Satoshi Morita
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Yakult Honsha
Isamu Okamoto
No relevant relationships to disclose
Narikazu Boku
No relevant relationships to disclose
Ichinosuke Hyodo
Honoraria - Bristol-Myers Squibb; Yakult Honsha